DICE Therapeutics
Craig Skinner has a diverse background in research, with experience in various scientific roles. Craig started their career at UCSF as a Research Associate I, where they maintained mouse colonies, performed genotyping, and conducted histology work. Craig then transitioned to Maxygen, Inc as a Research Associate I, contributing to the development of an aerosol vaccine against the plague and anthrax. Craig later pursued a graduate degree at UC Davis, where they worked as a Graduate Student Researcher, focusing on yeast lifespan and the mediation of calorie restriction and longevity. Following this, they joined USDA-WRRC as a Research Molecular Biologist, specializing in the purification of Shiga-like toxins and the generation of His-tagged Stx2 subunits. Craig currently works at DiCE Molecules as a Scientist, although specific details of their role are not provided. Overall, Craig Skinner's work experience showcases their expertise in molecular biology, biochemistry, and research in various fields.
Craig Skinner has a strong educational background in the field of Biochemistry and Molecular Biology. Craig completed their Bachelor of Science degree in Biochemistry/Cell biology at the University of California, Berkeley, from 1995 to 1999. Building upon this foundation, they pursued their academic career and obtained a Doctor of Philosophy degree in Biochemistry and Molecular Biology from the same institution, completing their studies from 2005 to 2011.
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.